A Century of Alkaptonuria: Evolving Insights into a Rare Metabolic Disorder
GenoMed Connect · 2025
DOI: 10.69709/genomc.2025.122212 ↗Kurz gefasst
Fachartikel in der Zeitschrift GenoMed Connect, 2025. Verfasst von Abhishek Vijukumar und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Alkaptonuria is believed to be a rare autosomal recessive disease caused by an imbalance in homogentisate 1,2 dioxygenase (HGD). HGA builds up in the body when the HGD enzyme isn't working correctly, despite the kidneys' ability to frequently remove it. The diagnosis of AKU may not occur until the ochronotic arthropathy manifests, which usually happens in adulthood. There is a paucity of information on the condition's early stages and infancy. The development of a dark color formation in urine, dried urine spot (DUS), immunofluorescence, Thioflavin T (Th-T) staining, Congo Red (CR) staining, and transmission electron microscopy (TEM) may all be used to detect this. Ascorbic acid, phenylalanine and tyrosine diet restrictions, and the only medication approved by the European Medicine Agency as the first disease-modifying treatment for individuals with AKU is nitisinone, which has demonstrated promise as an additional treatment for alkaptonuria.
Zitieren
APA
Vijukumar, A., ., K., Singh, H., Kalra, T., & Sharma, B. (2025). A Century of Alkaptonuria: Evolving Insights into a Rare Metabolic Disorder. GenoMed Connect. https://doi.org/10.69709/genomc.2025.122212
Vancouver
Vijukumar A, . K, Singh H, Kalra T, Sharma B. A Century of Alkaptonuria: Evolving Insights into a Rare Metabolic Disorder. GenoMed Connect. 2025. doi:10.69709/genomc.2025.122212
BibTeX
@article{Vijukumar2025,
author = {Vijukumar, Abhishek and ., Kamaljeet and Singh, Harkomal and Kalra, Tarun and Sharma, Bintoo},
title = {A Century of Alkaptonuria: Evolving Insights into a Rare Metabolic Disorder},
journal = {GenoMed Connect},
year = {2025},
doi = {10.69709/genomc.2025.122212}
}
EUVIMED